Search Results

You are looking at 121 - 130 of 1,415 items for :

  • "carcinoma" x
  • Refine by Access: All x
Clear All
Full access

Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon

Jarred Burkart, Dwight Owen, Manisha H. Shah, Sherif R. Z. Abdel-Misih, Sameek Roychowdhury, Robert Wesolowski, Sigurdis Haraldsdottir, Julie W. Reeser, Eric Samorodnitsky, Amy Smith, and Bhavana Konda

site of origin, stage, and biological features, influence treatment decisions. 2 Metastatic, high-grade, poorly differentiated neuroendocrine carcinomas (NECs) are typically aggressive tumors characterized by a Ki-67 level of >20% and a mitotic index

Full access

Evaluation of AJCC and an Alternative Tumor Classification System for Primary Vulvar Squamous Cell Carcinoma

Sarah T. Le, Pritesh S. Karia, Beverley J. Vollenhoven, Robert J. Besaw, Colleen M. Feltmate, and Chrysalyne D. Schmults

Background Vulvar cancer is the fourth most common gynecologic malignancy, accounting for 5% of female genitalia tumors. 1 Vulvar squamous cell carcinoma (vSCC) constitutes >90% of vulvar cancer. 2 In the United States, the age

Full access

First-Line Treatment of Widely Metastatic BRAF-Mutated Salivary Duct Carcinoma With Combined BRAF and MEK Inhibition

Victor T.G. Lin, Lisle M. Nabell, Sharon A. Spencer, William R. Carroll, Shuko Harada, and Eddy S. Yang

Salivary gland cancers are a heterogeneous collection of malignancies defined primarily by different histologies, which include adenoid cystic carcinoma (ACC), mucoepidermoid carcinoma, and salivary duct carcinoma (SDC). In particular, SDC is a

Full access

Predictors of Antiestrogen Recommendation in Women With Estrogen Receptor–Positive Ductal Carcinoma In Situ

Rondi M. Kauffmann, Leanne Goldstein, Emily Marcinkowski, George Somlo, Yuan Yuan, Philip H.G. Ituarte, Laura Kruper, Leslie Taylor, and Courtney Vito

Background Ductal carcinoma in situ (DCIS) is a premalignant breast lesion that has been increasingly diagnosed in the era of screening mammography, 1 and accounts for 20% to 25% of all new breast cancer diagnoses. 2 Marked atypia may be

Full access

Critical Evaluation of the Quality and Recommendations of Clinical Practice Guidelines for Nasopharyngeal Carcinoma

Yu-Pei Chen, Ya-Qin Wang, Wen-Fei Li, Lei Chen, Cheng Xu, Tai-Xiang Lu, Ai-Hua Lin, Ji-Jin Yao, Yang-Chan Li, Ying Sun, Yan-Ping Mao, and Jun Ma

the aim of improving guideline quality and likelihood of broad endorsement. 9 – 11 Nasopharyngeal carcinoma (NPC) is a unique head and neck (H&N) cancer with an uneven distribution: the age-standardized incidence rate ranges from 20 to 50 per 100

Full access

Cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary

Jennifer Shih, Babar Bashir, Karen S. Gustafson, Mark Andrake, Roland L. Dunbrack, Lori J. Goldstein, and Yanis Boumber

, including lung and breast carcinomas. 1 , 2 First-line treatment of lung adenocarcinomas that have a sensitizing EGFR mutation or ALK rearrangement includes the use of a tyrosine kinase inhibitor, such as erlotinib or crizotinib, whereas ceritinib is

Full access

Renaming Ductal Carcinoma in Situ: Would Removing “Carcinoma” Reduce Overtreatment?

Sara H. Javid, L. Christine Fang, Larissa Korde, and Benjamin O. Anderson

In both the medical literature and lay press, a flurry of controversy has arisen surrounding the treatment and, more specifically, the potential overtreatment of ductal carcinoma in situ (DCIS). Since the advent of population-based screening

Full access

Outcomes in Nonmetastatic Hormone Receptor–Positive HER2-Negative Pure Mucinous Breast Cancer: A Multicenter Cohort Study

Ryan Ying Cong Tan, Whee Sze Ong, Kyung-Hun Lee, Seri Park, Jabed Iqbal, Yeon Hee Park, Jeong Eon Lee, Jong Han Yu, Ching-Hung Lin, Yen-Shen Lu, Makiko Ono, Takayuki Ueno, Yoichi Naito, Tatsuya Onishi, Geok-Hoon Lim, Su-Ming Tan, Han-Byoel Lee, Jiwon Koh, Wonshik Han, Seock-Ah Im, Veronique Kiak Mien Tan, Nitar Phyu, Fuh-Yong Wong, Puay Hoon Tan, and Yoon-Sim Yap

Background Mucinous breast carcinoma (MuBC) is the third most common histologic subtype of breast cancer (BC) (∼3% of invasive BCs), after invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC). MuBC has a better prognosis in

Full access

Vascular Invasion and Metastasis is Predictive of Outcome in Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma

Ali A. Mokdad, Amit G. Singal, Jorge A. Marrero, Hao Zhu, and Adam C. Yopp

Background The incidence and mortality of hepatocellular carcinoma (HCC) have increased 2-fold during the past 2 decades, and it is currently the fastest growing cause of cancer-related death in the United States. 1 The 5-year survival rate

Full access

Carcinoma in situ of the Urinary Bladder: Review of Clinicopathologic Characteristics with an Emphasis on Aspects Related to Molecular Diagnostic Techniques and Prognosis

Nalan Nese, Ruta Gupta, Matthew H. T. Bui, and Mahul B. Amin

Edited by Kerrin G. Robinson

Novartis, Inc. References 1 Sesterhenn IA . Urothelial carcinoma in situ . In: Eble J Sauter G Epstein J Sesterhenn I , eds. World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Urinary System and